undamentalytics Newsletter
Sign in

Integra Lifesciences Holdings Corp cash flow statement

In fiscal 2025, Integra Lifesciences Holdings Corp's operations generated $50.4m of cash; it spent $81.4m on capital projects, leaving free cash flow of −$31.1m. It returned $221,000 through buybacks.

Cash flow statement

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2009Dec 20092010Dec 20102011Dec 20112012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Cash from operations14310610459538410511611520023120431226414012950140
Depreciation and amortisation403950533146597389111109423940414245—
Stock-based pay16172791015151722212120362820241920
Capital spending2537386942383347447870394842671048155
Free cash flow1186866−1011457169711221621652642227325−3186
Free cash flow after stock pay1025139−19131565249101141145228194531−5066
Share buybacks0318300————001000125275520—
Shares issued—00015202200035000——————

Free cash flow is cash from operations minus capital spending. Free cash flow after stock pay also subtracts stock-based compensation, a real cost to shareholders that the cash flow statement adds back. Dividends, buybacks and shares issued are cash amounts for the period.

Compare with peers

Head to head: IART vs MMSIIART vs PENIART vs ITGR

More: Health Care Equipment stocks compared, Health Care sector, rankings of US companies

Figures from Integra Lifesciences Holdings Corp's SEC filings (10-K and 10-Q), retrieved October 26, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Integra Lifesciences Holdings Corp.